Sanofi-backed Electra files for IPO to fund Phase 2/3 immunology drug

Sanofi-backed Electra files for a Nasdaq IPO to fund Phase 2/3 trials of ipsoprubart, its lead antibody for the rare disease sHLH. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push…

Kyle LaHucik · 2026-08-31

Biotech's IPO summer isn't over yet. Electra Therapeutics plans to begin public trading on the Nasdaq after the Labor Day holiday, according to a Friday IPO filing with securities regulators. While ...

Source: Endpoints News